Michael Kim, MD, on Developing More CREB Inhibitors in Pancreatic Cancer Moving Forward
Kim discussed the need for further CREB inhibitor combinations to target collateral pathways and improve patient outcomes.
Michael Kim, MD, on Genetics and the Need for Novel Therapies in Pancreatic Cancer
Kim detailed the specifics of his research from the American Association for Cancer Research Annual Meeting 2021 focusing on novel therapies to target mutations and upstream or downstream pathways.
Michael Kim, MD, Discusses Study on Mutant p53 and Oncogenic KRAS in Pancreatic Cancer
The MD Anderson expert discussed the main takeaway from the data published during the virtual AACR Annual Meeting, while looking forward to what comes next with these genetic drivers.
2 Clarke Drive Cranbury, NJ 08512